Akebia Therapeutics, Inc. filings document the regulatory record of a commercial-stage biopharmaceutical company focused on kidney disease therapeutics. Its 8-K reports include quarterly and annual operating results, Vafseo® commercialization updates, pipeline disclosures, Regulation FD presentations, and material agreements tied to licensing, supply, and corporate facilities.
Akebia’s proxy materials describe board composition, committee assignments, director elections, executive compensation, equity plans, and shareholder voting matters. The filing record also covers governance changes, Nasdaq-listed common stock matters, risk and business disclosures related to commercial products, clinical programs, collaborations, lease obligations, and capital-structure activity.
Akebia Therapeutics CEO and President John P. Butler reported new equity awards on January 30, 2026. He received 743,000 shares of common stock as restricted stock units at a price of $0.00 per share, bringing his directly held common stock to 3,463,849 shares.
He was also granted a stock option for 1,115,000 shares at an exercise price of $1.41 per share, expiring on 01/30/2036. These options vest over four years, while the restricted stock units vest in three equal annual installments, both subject to his continued service. An additional 159,928 shares are held indirectly through the Dorothy Butler Revocable Trust.
Akebia Therapeutics executive Carolyn M. Rucci, SVP and Chief Legal Officer, filed an initial ownership report showing her equity position in the company. She reports beneficial ownership of multiple blocks of Akebia common stock, including 171,816 shares held directly and additional shares linked to restricted stock unit grants.
The filing also lists several employee stock options to buy Akebia common stock, with exercise prices ranging from $0.63 to $2.88 per share and expiration dates between 2031 and 2035. These options generally vest over four years, with 25% vesting after one year and the remainder in equal quarterly installments, subject to continued service.
A shareholder of Akebia Therapeutics, Inc. has filed a notice of proposed sale of 34951 shares of common stock through Morgan Stanley Smith Barney LLC on the Nasdaq. The filing lists an aggregate market value of 48739.00 for these shares.
The shares are part of a much larger base of 265365993 shares outstanding. They were acquired as restricted stock on 01/31/2026, with a listed payment date of 02/02/2026. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Akebia Therapeutics, Inc. shareholder plans to sell common stock under Rule 144. The notice covers the proposed sale of 84,829 shares of Akebia common stock, with an aggregate market value of $118,294.00. The shares are to be sold through Morgan Stanley Smith Barney LLC on the Nasdaq market, with an approximate sale date of February 2, 2026.
The securities were acquired as restricted stock from Akebia Therapeutics, Inc. on January 31, 2026, with 84,829 shares granted and payment noted as non-cash. The filing also notes total shares outstanding of 265,365,993 common shares, providing context for the size of the proposed sale.
A shareholder of Akebia Therapeutics, Inc. filed a Rule 144 notice to sell 67,658 shares of common stock on the Nasdaq through Morgan Stanley Smith Barney LLC, for an aggregate market value of $94,349. These shares were acquired as restricted stock from Akebia on January 31, 2026, with payment dated February 2, 2026. The filing notes that 265,365,993 shares of the issuer’s common stock are outstanding.
Akebia Therapeutics insider-related holders filed a notice to sell up to 341,305 shares of common stock under Rule 144. The proposed sale has an aggregate market value of $475,950.00 and is expected to be executed through Morgan Stanley Smith Barney LLC on Nasdaq around 02/02/2026.
The filing notes that these shares are common stock and indicates that 265,365,993 shares of this class were outstanding, providing scale for the planned sale. The shares to be sold were acquired as restricted stock from Akebia Therapeutics, Inc. on 01/31/2026.
An unnamed holder of Akebia Therapeutics, Inc. common stock has filed a notice to sell 69772 shares under Rule 144. The planned sale, with an aggregate market value of 97297.00, is to be executed through Morgan Stanley Smith Barney LLC on the Nasdaq around 02/02/2026. The securities are restricted stock originally acquired from Akebia on 01/31/2026, and the filing notes that total common shares outstanding are 265365993.
Akebia Therapeutics entered into a long-term lease to relocate its corporate headquarters to new office and lab space in Waltham, Massachusetts. The lease covers approximately 43,474 square feet and includes an initial annual rent of $898,317 for the office area and $1,046,920 for the lab area, subject to scheduled yearly increases. The initial term runs 84 months from the office commencement date, with a security deposit of $810,515 provided via letter of credit and an option for a five-year extension.
Akebia also approved amended executive severance agreements for its CEO, John P. Butler, and CFO, Erik J. Ostrowski, to better align with market practices. These agreements provide specified periods of salary continuation, bonus payments, COBRA premium reimbursements, and accelerated vesting of equity awards upon certain terminations, particularly in connection with a change in control, contingent on a release of claims and ongoing restrictive covenants.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Akebia Therapeutics, Inc. as of 12/31/2025. BlackRock reports beneficial ownership of 19,219,819 Akebia shares, representing 7.2% of the outstanding common stock. It has sole voting power over 18,844,036 shares and sole dispositive power over 19,219,819 shares, with no shared voting or dispositive power.
The filing explains that these holdings are attributed to certain BlackRock business units and are held in the ordinary course of business, not for the purpose of changing or influencing control of Akebia. Various underlying clients have rights to dividends or sale proceeds, but no single person has more than 5% of Akebia’s outstanding common shares.
Akebia Therapeutics, Inc. furnished an update focused on its Vafseo® (vadadustat) commercial business and future growth plans. The company issued a press release outlining key corporate updates, an outlook on upcoming milestones, and highlighted its next anticipated growth driver in its mid-stage rare kidney disease pipeline. It also shared an overview of expected fourth quarter 2025 Vafseo net product revenue.
Akebia is also making a corporate presentation available, which its spokespersons plan to use at investor and analyst meetings, including sessions coinciding with the 44th Annual J.P. Morgan Healthcare Conference. Both the press release and the presentation are attached as exhibits and are being furnished, not filed, under the securities laws.